Asia N = 97 | Latin Am N = 46 | ME/NA N = 39 | Aus/Can N = 39 | p value | |
---|---|---|---|---|---|
Building capacity (%) | |||||
Science and research | 51.5 | 50.0 | 56.4 | 46.2 | 0.84 |
Skilled nurses | 50.5 | 41.3 | 51.3 | 38.5 | 0.48 |
Research infrastructure | 29.9a | 58.7b | 30.8a, b | 41.0a, b | 0.01 |
National statistics | 26.8a | 37.0a, b | 51.3a, b | 56.4b | 0.003 |
Public education | 42.3 | 47.8 | 46.2 | 33.3 | 0.56 |
Developing evidence (%) | |||||
Study of local etiology | 23.7 | 37.0 | 28.2 | 33.3 | 0.38 |
Personalized therapy | 36.1a | 82.6b | 20.5a | 48.7a | < 0.001 |
Developing guidelines | 23.7a | 47.8b | 12.8a | 51.3b | < 0.001 |
International networks | 52.6a, b | 63.0b | 30.8a | 66.7b | 0.01 |
Local communication | 36.1a | 34.8a | 10.3b | 56.4a | < 0.001 |
Removing barriers (%) | |||||
Out-of-pocket costs | 38.1a, b | 47.8b | 10.3c | 20.5a, c | < 0.001 |
Disparities in access | 37.1a, c | 69.6b | 23.1a | 53.8b, c | < 0.001 |
High cost to payers | 42.3 | 56.5 | 38.5 | 53.8 | 0.22 |
Early detection | 45.4 | 50.0 | 46.2 | 41.0 | 0.88 |
Reimbursement | 43.3a, b | 45.7a, b | 28.2b | 61.5a | 0.03 |
Promoting advocacy (%) | |||||
Patient empowerment | 26.8a | 39.1a, b | 23.1a, b | 53.8b | 0.008 |
Managing survivorship | 12.4a | 17.4a | 0.0b | 33.3a | 0.004 |
Quality of life | 19.6 | 28.3 | 20.5 | 33.3 | 0.31 |
Metastatic disease | 36.1 | 26.1 | 33.3 | 28.2 | 0.63 |
Organized advocacy | 13.4a, c | 43.5b | 28.2c | 5.1a | < 0.001 |